Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2012

View Archived Issues

Shionogi reports milestones of second quarter of fiscal 2012

Nonviral gene therapy for heart failure presented at AHA meeting

Kancera reports preclinical data for pancreatic cancer compounds

Phase III results reported for Ruconest in acute hereditary angioedema

Senesco Technologies expands study of SNS01-T

Auxilium and Pfizer to terminate European agreement for Xiapex

Auxilium seeks approval of new indication for Xiaflex in the U.S.

Clinical benefit of GLPG-0634 in rheumatoid arthritis confirmed in phase IIa trial

FDA grants fast track status for etirinotecan pegol in metastatic breast cancer

Albireo obtains FDA orphan drug designation for A-4250 in liver diseases

Catalyst Pharmaceutical reports results from phase IIb CPP-109 trial

Signifor recommended by FDA advisory committee for Cushing's disease

T-3256336 proven to be a highly effective inhibitor of tumor growth in vivo

IMA-901 receives FDA orphan designation, phase III study completes enrollment

Cornerstone acquires U.S. rights to Chiesi's Bethkis for cystic fibrosis

Merck & Co. presents novel BACE inhibitors

Laboratoire Biodim discloses new agents for HIV infection

Ironwood Pharmaceuticals submits IND for antianxiety drug candidate

Sloan-Kettering Institute for Cancer Research patents new HSP 90 inhibitors

Nektar Therapeutics synthesizes promising thymidylate synthase inhibitor

FDA accepts to review NDA for suvorexant in insomnia

Scientists at Vertex Pharmaceuticals patent new protein kinase inhibitors

Merck & Co. prepares novel agents for diabetes and obesity

Pfizer divulges new lpxC inhibitors for bacterial infections

Cryopraxis and CellPraxis plan phase III trial of cell therapy for refractory angina

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...